Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T15:33:39.182Z.
Calculation as of: 2026-10-06T15:33:39.182Z.
Quote observation: 2026-10-06T15:26:41.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: d2baa5019f568993ecceb1943c30cf17443c8d153a00c2cc4d930c3e59df60e4
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Liminatus Pharma, Inc. Class A Common Stock
Market Cap
$5.21M
EV/EBIT Ratio
N/A
| NAME | MARKET CAP | EV/EBIT RATIO |
|---|---|---|
| Liminatus Pharma, Inc. Class A Common Stock (LIMN) | $5.21M | N/A |
| Pulmatrix, Inc. (PULM)vs › | $5.22M | N/A |
| Lunai Bioworks Inc. (LNAI)vs › | $5.19M | N/A |
| Intelligent Bio Solutions Inc. (INBS)vs › | $5.27M | N/A |
| Alzamend Neuro Inc (ALZN)vs › | $5.29M | N/A |
| Gelteq Limited Ordinary Shares (GELS)vs › | $5.32M | N/A |
| Imunon, Inc. (IMNN)vs › | $5.04M | N/A |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $5.01M | N/A |
| CalciMedica, Inc. (CALC)vs › | $4.94M | N/A |
| Acurx Pharmaceuticals, Inc. (ACXP)vs › | $5.51M | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
